Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 3/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.35 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.35 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.35 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.35 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.35 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.31 |
| ▸ | PTGFR | P43088 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24088650 | 0.78 | AKT1 (0.33) | — | |
| SCHEMBL22490785 | 0.74 | PDE5A (0.39) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL22490776 | 0.72 | CTPS1 (0.44) | — | |
| SCHEMBL12614953 | 0.70 | HCAR3 (0.44) | — | |
| SCHEMBL24716805 | 0.69 | HDAC3 (0.31) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL19900788 | 0.68 | — | — | |
| SCHEMBL21044072 | 0.67 | HDAC1 (0.39) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL22981913 | 0.66 | BAZ2A (0.33) | HDAC1 | |
| SCHEMBL28789041 | 0.66 | NPC1 (0.36) | HDAC1HDAC3HDAC2HDAC6 | |
| SCHEMBL23573214 | 0.65 | ALDH1A1 (0.40) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183229-A1 | Compounds | SYGNATURE DISCOVERY LIMITED (GB) | 2023-06-15 | — | — | US | disclosed |
| US-20210380575-A1 | COMPOUNDS | SYGNATURE DISCOVERY LIMITED (GB) | 2021-12-09 | — | — | US | disclosed |
| EP-3717465-A1 | COMPOUNDS | Step Pharma S.A.S. (FR) | 2020-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183229-A1 | Compounds | UGT1A1, CYP1A1, CYP1B1 | HDAC1 552/4885HDAC3 843/4885HDAC4 2152/4885 |
| US-20210380575-A1 | COMPOUNDS | UGT1A1, CYP1A1, CYP1B1 | HDAC1 552/4885HDAC3 843/4885HDAC4 2152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.